
Agilent Technologies, Inc.
Agilent
Agilent Technologies, Inc. is a global leader in analytical and life sciences instrumentation, headquartered in Santa Clara, California. Spun off from Hewlett-Packard in 1999, Agilent designs and manufactures chromatography, mass spectrometry, spectroscopy, cell analysis, and molecular diagnostics systems that operate in more than 285,000 laboratories worldwide. In FY2025 the company generated US$6,948 million in revenue, up 6.7% year-over-year, with core Q4 growth of 7.2%, employing approximately 18,100 people.
Strengths:
• Laboratory franchise – industry-standard chromatography and mass spectrometry platforms with deep installed base and recurring consumables revenue
• Diagnostics expansion – the US$950 million Biocare Medical acquisition (2026) added 300+ IHC and FISH assays, strengthening oncology testing
• Financial resilience – 6.7% revenue growth with accelerating core demand demonstrates successful post-downturn recovery
• Global manufacturing – self-manufacturing model with facilities across the US, Europe and Asia ensures supply-chain control
Weaknesses:
• Pharma capex exposure – spending slowdowns in biopharma capital equipment, driven by tariffs and macro uncertainty, pressured early-2025 demand
• Currency volatility – global FX swings periodically compress reported revenue and margins
• Competition in China – domestic instrument makers are intensifying price competition in Agilent's second-largest marketRead MoreShow Less
Strengths:
• Laboratory franchise – industry-standard chromatography and mass spectrometry platforms with deep installed base and recurring consumables revenue
• Diagnostics expansion – the US$950 million Biocare Medical acquisition (2026) added 300+ IHC and FISH assays, strengthening oncology testing
• Financial resilience – 6.7% revenue growth with accelerating core demand demonstrates successful post-downturn recovery
• Global manufacturing – self-manufacturing model with facilities across the US, Europe and Asia ensures supply-chain control
Weaknesses:
• Pharma capex exposure – spending slowdowns in biopharma capital equipment, driven by tariffs and macro uncertainty, pressured early-2025 demand
• Currency volatility – global FX swings periodically compress reported revenue and margins
• Competition in China – domestic instrument makers are intensifying price competition in Agilent's second-largest market
Listed market data
A · NYSE · weeklyHistory →- Market cap
- $48.8 B
- Share price
- USD 170.38
- 1Y change
- +22.0%
- Recent change
- -2.8%
- IPO price
- +467.9%
- Revenue (TTM)
- $7.4 B
11-19 → 11-20
USD 30.00 · from 1999-11-18
Financial history
Full market history- 2026-11USD 170.38$48.8 B-1.5%
- 2026-10USD 172.97$48.8 B+0.4%
- 2026-09USD 172.31$49.3 B+12.2%
- 2026-08USD 153.56$44 B+11.0%
- 2026-07USD 138.37$39.6 B+4.2%
- 2026-06USD 132.83$38 B-2.0%
- 2026-05USD 135.53$38.8 B+17.3%
- 2026-04USD 115.55$33.1 B+1.4%
- 2026-03USD 113.98$32.6 B-6.1%
- 2026-02USD 121.38$34.7 B-9.3%
- 2026-01USD 133.85$38.3 B-1.6%
- 2025-12USD 136.07$38.9 B—
Ownership & Control
Shareholding as of 2026-06-30- Controlling entity
- Publicly held — no controlling shareholder disclosed
- Company type
- Brand & Manufacturer
- Insiders
- 0.19%
- Institutions
- 95.41%(1,659 holders)
- Free float
- 95.59%
Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.
In the press
All coverage →5 latest headlines1- JPMorgan lifts target for Agilent Technologies stock to USD 195 - ad-hoc-news.dewww.ad-hoc-news.de2026-10-20
- Agilent Technologies Inc. stock underperforms Monday when compared to competitors - MarketWatchwww.marketwatch.com2026-10-19
- $1000 Invested In Agilent Technologies 10 Years Ago Would Be Worth This Much Today - Benzingawww.benzinga.com2026-10-19
- Agilent Technologies Inc. Advanced Charts | AGIL - Barron'swww.barrons.com2026-10-16
- Agilent acquires Proscia in deal worth up to $270mmedicaldevice-network.com2026-10-14
• Liquid and gas chromatography, mass spectrometry and spectroscopy systems
• Cell analysis and material testing equipment
• Equipment operating in more than 285,000 laboratories globally
Medical Diagnostics – Core Business
• In-vitro diagnostics IVD and pathology detection platforms
• 2026 acquisition of Biocare Medical added 300+ IHC and FISH antibody assays and instruments
Materials & Applied Testing – Core Business
• Materials characterization, chemical analysis and environmental testing solutions
• Semiconductor and electronics industry measurement tools
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2025 | $6.9 B | $1.3 B |
| 2024 | $6.5 B | $1.3 B |
| 2023 | $6.8 B | $1.2 B |
| 2022 | $6.8 B | $1.3 B |
| 2021 | $6.3 B | $1.2 B |
Annual results from company filings (SEC XBRL), converted to US dollars.
Annual and interim reports published by the exchange or regulator. Links open the official source — files are not hosted on VerityRank.
| Year | Filing | Filed | Source | |
|---|---|---|---|---|
| 2026 | 8-K | 2026-09-08 | SEC EDGAR | Open ↗ |
| 2026 | 10-Q | 2026-09-01 | SEC EDGAR | Open ↗ |
| 2026 | 8-K | 2026-08-26 | SEC EDGAR | Open ↗ |
| 2026 | 8-K | 2026-06-25 | SEC EDGAR | Open ↗ |
| 2026 | 10-Q | 2026-06-01 | SEC EDGAR | Open ↗ |
| 2026 | 8-K | 2026-05-27 | SEC EDGAR | Open ↗ |
| 2026 | 8-K | 2026-05-04 | SEC EDGAR | Open ↗ |
| 2026 | 8-K | 2026-04-03 | SEC EDGAR | Open ↗ |
| 2026 | 8-K | 2026-03-20 | SEC EDGAR | Open ↗ |
| 2026 | 8-K | 2026-03-06 | SEC EDGAR | Open ↗ |
Links point to the issuer’s official disclosure platform. We store no filings.
Quick Facts
Headquarters
Founded
Employees
Revenue
Market cap
Factories
Presence
Listing
NYSE: ACategories
10 categories · scroll for more
Related
Similar listed companies
- Thermo Fisher Scientific Inc.· $310 B
- The Linde Group· $273 B
- Abbott Laboratories· $234 B
- Siemens AG· $223 B
- Danaher Corporation· $206 B
- KLA· $173 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website NYSE: A , Agilent Investor Financial Summary
Agilent Completes Biocare Medical Acquisition
Agilent Q4 FY2025 Results
Agilent Technologies – Wikipedia
